Alphabet Inc’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-53,024
| Closed | -$208K | – | 46 |
|
|
2023
Q3 | $208K | Hold |
53,024
| – | – | 0.01% | 40 |
|
|
2023
Q2 | $172K | Sell |
53,024
-1
| -0% | -$3 | 0.01% | 43 |
|
|
2023
Q1 | $191K | Hold |
53,025
| – | – | 0.01% | 46 |
|
|
2022
Q4 | $1.71M | Hold |
53,025
| – | – | 0.1% | 36 |
|
|
2022
Q3 | $2.22M | Hold |
53,025
| – | – | 0.11% | 37 |
|
|
2022
Q2 | $2.24M | Hold |
53,025
| – | – | 0.12% | 41 |
|
|
2022
Q1 | $3.6M | Hold |
53,025
| – | – | 0.12% | 42 |
|
|
2021
Q4 | $6.44M | Hold |
53,025
| – | – | 0.16% | 42 |
|
|
2021
Q3 | $7.47M | Hold |
53,025
| – | – | 0.18% | 31 |
|
|
2021
Q2 | $14.6M | Hold |
53,025
| – | – | 0.3% | 22 |
|
|
2021
Q1 | $11.3M | Hold |
53,025
| – | – | 0.46% | 23 |
|
|
2020
Q4 | $12.8M | Hold |
53,025
| – | – | 0.62% | 19 |
|
|
2020
Q3 | $5.59M | Hold |
53,025
| – | – | 0.26% | 17 |
|
|
2020
Q2 | $5.2M | Hold |
53,025
| – | – | 0.24% | 20 |
|
|
2020
Q1 | $3.98M | Hold |
53,025
| – | – | 0.26% | 20 |
|
|
2019
Q4 | $4.31M | Hold |
53,025
| – | – | 0.26% | 22 |
|
|
2019
Q3 | $6.47M | Hold |
53,025
| – | – | 0.19% | 18 |
|
|
2019
Q2 | $9.52M | Hold |
53,025
| – | – | 0.18% | 16 |
|
|
2019
Q1 | $8.48M | Hold |
53,025
| – | – | 0.44% | 13 |
|
|
2018
Q4 | $13.8M | Hold |
53,025
| – | – | 1.63% | 12 |
|
|
2018
Q3 | $12.9M | Hold |
53,025
| – | – | 1.24% | 12 |
|
|
2018
Q2 | $12.5M | Buy |
+53,025
| New | +$15.5M | 1.05% | 11 |
|
Other funds holding EVLO
Alphabet Inc's EVLO Position: Q4 2023 in Review
Alphabet Inc sold out of Evelo Biosciences, Inc. Common Stock (EVLO) in Q4 2023, closing a stake of 53,024 shares — an estimated $208K sold.
Alphabet Inc first reported a position in EVLO in Q2 2018 and held it in 22 quarters. The position peaked at $14.6M in Q2 2021. 2 funds tracked by Wall St. Rank hold EVLO as of Q4 2023.
- Alphabet Inc reported no remaining Evelo Biosciences, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
- Alphabet Inc sold 53,024 Evelo Biosciences, Inc. Common Stock shares in Q4 2023, an estimated $208K.
- Alphabet Inc first reported a position in Evelo Biosciences, Inc. Common Stock in Q2 2018 and held it in 22 quarters.
- Alphabet Inc's Evelo Biosciences, Inc. Common Stock position peaked at $14.6M in Q2 2021.
- 2 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q4 2023.
Based on Alphabet Inc's 13F filing for Q4 2023, filed 9 Feb 2024.